Compass Therapeutics, Inc.

NASDAQ:CMPX

Biotechnology

Healthcare
$0.61 -1.46%

-$0.03 today

Market cap
$109.26M
Beta
0.74
P/E (TTM)
-5.5
EPS (TTM)
-$0.37
52W Low $1.61High $6.88

Volume 2.90M

Average 7.64M

CMPX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Compass Therapeutics, Inc.NASDAQ: CMPX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $5.07M rose 101.8% year over year, ahead of the +20.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 178.0% from the prior quarter. Over 3 fiscal years it compounded at +16.2% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +101.8% holds above the trailing-twelve-month pace of +20.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.07M+178.0% QoQ
Last fiscal yearDec 2025
$8.37M-2.2% YoY
LTMMar 2026
$10.93M+20.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+101.8%——
1 year-2.2%——
3-year CAGR+16.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
8.37M USD
Year-over-year change
-2.2%
4-year CAGR
+20.0%

Stock-Based Compensation vs competitors

How CMPX compares with its peers on the latest reported figures

  • CMPX's LTM Mar 2026 stock-based compensation of $10.93M is the 5th largest of the 11 companies compared; the peer median is $7.97M.
  • Its year-over-year change of +20.5% is the 4th highest of 10, against a peer median of +2.5%.
  • Over three fiscal years its annual growth of +16.2% compares with a peer median of +5.8%.
CMPX Competitors Peer median
Stock-Based Compensation for CMPX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$19.48M -28.2%+8.7%22.1%
GOSSGossamer Bio, Inc.LTM Mar 2026$14.45M -16.0%-37.2%26.0%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$13.16M -4.7%-2.3%—
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$12.55M +2.5%+2.8%18.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$10.93M +20.5%+16.2%—
OCGNOcugen, Inc.LTM Mar 2026$9.22M +22.1%-9.9%206.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$6.73M +88.8%+25.6%—
OMEROmeros CorporationLTM Mar 2026$5.74M +13.3%—58.0%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$5.38M ——4.6%
MNPRMonopar Therapeutics Inc.LTM Mar 2026$4.07M +87.9%+43.4%—
BCYCBicycle Therapeutics plcLTM Mar 2026$2.68M -107.0%+13.8%4.2%
Peer median (excluding CMPX) $7.97M+2.5%+5.8%22.1%

Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(82.18M)(39.23M)(42.49M)(49.38M)(66.49M)
Depreciation & Amortization1.62M1.9M1.89M1.75M(1.4M)
Deferred Income Tax50.58M0000
Stock-Based Compensation4.03M5.33M6.12M8.56M8.37M
Change in Working Capital6.25M(1.26M)(2.91M)(4.14M)9.18M
Accounts Receivables00000
Inventory00000
Accounts Payables(194K)2.52M708K(1.84M)(664K)
Other Working Capital6.44M(3.78M)(3.62M)(2.3M)9.84M
Other Non-Cash Items41K(871K)5.97M(1.65M)1.2M
Operating Cash Flow(19.67M)(34.13M)(40.62M)(44.86M)(49.14M)
Capital Expenditures(1.57M)(212K)(30K)(44K)(25K)
Acquisitions (Net)116K176K000
Purchases of Investments0(200.12M)(155.42M)(88.16M)(194.56M)
Sales of Investments048.96M182.41M134.97M101.28M
Other Investing Activities(318K)(150.99K)27K00
Investing Cash Flow(1.77M)(151.2M)26.97M46.77M(93.31M)
Debt Repayment———00
Common Stock Issued128.27M76.24M3.09M18.11M130.64M
Common Stock Repurchased00(159)00
Dividends Paid00000
Other Financing Activities(281K)(480K)(159K)(775K)(1.03M)
Financing Cash Flow118.61M75.76M2.94M17.34M129.61M
Effect of Forex Changes00000
Net Change in Cash97.18M(109.57M)(10.72M)19.26M(12.84M)
Free Cash Flow(21.23M)(34.34M)(40.65M)(44.9M)(49.17M)

Compass Therapeutics, Inc.

NASDAQ:CMPX

Intrinsic Alpha fair value

Locked

Current Price

$0.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.